The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Search for "risankizumab-rzaa"

Search results for: risankizumab-rzaa

FDA Approves Risankizumab-rzaa for PsA

April 20, 2022 • By Michele B. Kaufman, PharmD, BCGP

Two recent trials demonstrated the safety and efficacy of risankizumab-rzaa for the treatment of adults with active psoriatic arthritis.... [Read More]

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: FDA approval, PsA, Psoriatic Arthritis, risankizumab-rzaa, U.S. Food and Drug Administration (FDA)

Psoriatic Arthritis Treatment Update

October 13, 2021 • By Mary Choy, PharmD, BCGP, FASHP

About 30% of patients with psoriasis have psoriatic arthritis (PsA), a complex, multi-faceted, chronic, inflammatory musculoskeletal and skin disease for which the treatment has changed considerably over the past few years.1 Biosimilars and other new drugs have become a therapeutic turning point for many patients suffering from rheumatic illnesses, including PsA. The treatment of PsA… [Read More]

Filed Under: Conditions, Drug Updates, Guidelines Tagged With: PsA Resource Center, Psoriatic Arthritis

ACR Leads AMA Resolution on Payer Financial Incentives to Patients to Switch Treatment

May 22, 2021 • By From the College

Spurred by a recent Cigna policy, the ACR will lead a resolution to oppose insurance companies providing financial incentives for patients to switch treatments. Several specialties are cosponsoring the resolution for a special meeting of the AMA House of Delegates in June. ... [Read More]

Filed Under: Legislation & Advocacy Tagged With: AMA House of Delegates (HOD), insurance

Cigna Offers Patients Financial Incentive to Switch Treatments

April 16, 2021 • By From the College

The ACR has sent a letter to Cigna expressing opposition to the initiative, which jeopardizes patients’ health, interferes with medical decision making, undermines the doctor-patient relationship and may disproportionately affect patients of lower socioeconomic status.... [Read More]

Filed Under: Drug Updates, Legislation & Advocacy Tagged With: insurance, non-medical switching

FDA Approves AbbVie’s New Rheumatoid Arthritis Drug

August 19, 2019 • By Reuters Staff

(Reuters)—The U.S. Food and Drug Administration (FDA) on Friday approved AbbVie Inc.’s new treatment for rheumatoid arthritis (RA), a win for the drugmaker seeking to widen its portfolio as its blockbuster flagship therapy Humira (adalimumab)‎‎ faces competition. The drug, Rinvoq (upadacitinib), is a JAK inhibitor. It is set to compete with Pfizer Inc.’s Xeljanz (tofacitinib)… [Read More]

Filed Under: DMARDs & Immunosuppressives, Drug Updates Tagged With: AbbVie Inc, FDA, FDA approval, Rheumatoid Arthritis (RA), U.S. Food and Drug Administration (FDA), upadacitinib

FDA Approves Risankizumab, Adds Stronger Warning to Sleep Medications

May 29, 2019 • By Michele B. Kaufman, PharmD, BCGP

The FDA has approved rizankixumab to treat adults with plaque psoriasis and added boxed warnings to sleep medications…... [Read More]

Filed Under: Biologics & Biosimilars, Drug Updates, Safety Tagged With: FDA, plaque psoriasis, rizankixumab, Sleep, U.S. Food and Drug Administration (FDA)

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)